ʻO Tirzepatide kahi lāʻau lapaʻau hou e hōʻike ana i kahi holomua nui i ka mālama ʻana i ka maʻi diabetes type 2 a me ka momona. ʻO ia ka mua ʻelua agonist o ka glucose-dependent insulinotropic polypeptide (GIP) a me ka glucagon-like peptide-1 (GLP-1) receptors. Hoʻokaʻawale kēia ʻano hana ʻokoʻa mai nā lāʻau lapaʻau i loaʻa a hiki i nā hopena ikaika i ka mālama ʻana i ka glucose koko a me ka hōʻemi kaumaha.
Ma ka hoʻoulu ʻana i nā mea loaʻa GIP a me GLP-1, hoʻomaikaʻi ʻo Tirzepatide i ka huna ʻana o ka insulin a me ka naʻau, hoʻemi i ka huna ʻana o ka glucagon, hoʻolohi i ka hoʻokuʻu ʻana o ka ʻōpū, a hoʻemi i ka makemake.
Hāʻawi ʻia ʻo Tirzepatide ma ke ʻano he hoʻokele subcutaneous i hoʻokahi pule i kēlā me kēia pule. Hoʻomaikaʻi nui ia i ka mana glycemic a hōʻemi i ke kaumaha o ke kino, pinepine ma mua o ka hana o nā lāʻau lapaʻau i loaʻa i kēia manawa. Eia kekahi, ua ʻike ʻia nā pōmaikaʻi cardiovascular.
ʻO nā hopena ʻaoʻao maʻamau ka maʻi ʻōpū, me ka nausea, ka maʻi paʻi, a me ka luaʻi ʻana, ʻo ia ka mea maʻamau i ka maʻalahi a me ka haʻahaʻa i ke koʻikoʻi a hoʻemi i ka manawa.
ʻO ka holoʻokoʻa, ʻo ka hoʻomohala ʻana o Tirzepatide e hōʻailona i kahi palena hou i ka mālama ʻana i nā maʻi metabolic, e hāʻawi ana i kahi mea hana ikaika no ka mālama ʻana i ka maʻi diabetes a me ka momona.
Ka manawa hoʻouna: Sep-01-2025